Group 1 - Dingtang Health has launched Novartis' innovative drug, Acrivastine Hydrochloride Tablets (brand name: Noreda), in its pharmacy, completing its first service order in Beijing within two months of domestic approval [1] - The company has also partnered with Yiteng Pharmaceutical to introduce another innovative anti-tumor drug, Lacosamide Hydrochloride Tablets, which was approved for market entry on May 29 this year [1] - Since 2025, Dingtang Health has implemented the "New Specialty Drug. Life Ark Plan," successfully increasing patient access and adherence to multiple innovative drugs [1] Group 2 - For the first half of 2025, Dingtang Health reported revenue of 2.327 billion yuan, a year-on-year increase of 2.6%, with a gross profit of 816 million yuan and a gross margin of 35% [2] - The company recorded a loss of 52.02 million yuan, narrowing the loss by 42.1% compared to the same period in 2024, while the adjusted net profit loss was 5.759 million yuan, a reduction of 78.2% year-on-year [2] - Dingtang Health plans to focus on user lifecycle health management and full-course management strategies, enhancing its smart center warehouse construction and integrating wholesale and retail pharmaceutical goods [2]